JAZZ Healthcare

Jazz Pharmaceuticals plc

$229.74+7.13%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Ireland
Market cap: 14.9B USD
Enterprise value: 16.4B USD
Full-time employees: 2,890

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: higher risk than most peers: more debt relative to equity (0.91× vs a peer median of 0.22×)higher risk: more debt vs equity (0.91× vs peers 0.22×)

Ranks #238 of 1,157 healthcare companies (top 21%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $766M vs $706M spent repurchasing shares over the 3 fiscal years to 2025. Shares outstanding changed +2.7% from December 2022 to July 2026.
Over three fiscal years Jazz Pharmaceuticals recorded $766M of stock-based pay expense and spent $706M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Jazz Pharmaceuticals recorded $766M of stock-based pay expense and spent $706M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Jazz Pharmaceuticals made a profit per share in its latest year after a loss the year before.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in 2020 to $4.3B in 2025.
Jazz Pharmaceuticals's fiscal-year revenue rose in each of the five years to 2025, from $2.4B to $4.3B.
Profit is backed by cash. Free cash flow is 169% of reported profit.
Jazz Pharmaceuticals's free cash flow is 169% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

65/ 100

Oct 5 65 → Nov 4 65

Valuation

Is the price right?

72/100

Moderate▼ 3 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 3.5% (existing holders diluted)

Valuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 75 → 72

Share price +11.1%-3

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield6.3%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 3.26Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.3%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.32Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield10.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield32.2%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

80/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.7%

Why

Stronger than most peers on:

▲ EPS growth
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth6.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.13Sector median: 0.0584 · MAD: 0.0840

Revenue growth12.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.67Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

79/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 20.3 points to 19.5%

Why

Stronger than most peers on:

▲ ROA
▲ Operating margin
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin19.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.02Sector median: 0.0706 · MAD: 0.1217

Return on assets8.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.27Sector median: 0.0166 · MAD: 0.0537

Return on invested capital9.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.47Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin91.4%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity19.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 27 → 28

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.36

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.78Sector median: 0.6250 · MAD: 0.3380

Current ratio1.78×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.58Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.91×

SEC filings · latest balance sheetReported value33% base weight · Z-score -3.36Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Jazz Pharmaceuticals

Is Jazz Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 3, 2026) was mixed: some things better, some worse: operating margin rose 20.3 points to 19.5%; share count up 3.5%. Its overall score is unchanged at 65/100 since Oct 28, 2026.
How is Jazz Pharmaceuticals valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 72/100 against 1,393 healthcare peers. Earnings yield 6.3% vs a peer median of 1.5% (stronger than 84% of peers).Earnings yield 6.3% vs peers 1.5% (stronger than 84% of peers).
Is Jazz Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 80/100 against 1,393 healthcare peers. Revenue growth 12.6% vs a peer median of 6.1% (stronger than 67% of peers).Revenue growth 12.6% vs peers 6.1% (stronger than 67% of peers).
How profitable is Jazz Pharmaceuticals?: More profitable than most of its peers. Profitability scores 79/100 against 1,393 healthcare peers. Return on assets 8.5% vs a peer median of 1.7% (stronger than 87% of peers).Return on assets 8.5% vs peers 1.7% (stronger than 87% of peers).
How risky is Jazz Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.36 vs a peer median of 0.63 (stronger than 73% of peers).Beta 0.36 vs peers 0.63 (stronger than 73% of peers). Debt / equity 0.91× vs a peer median of 0.22× (weaker than 79% of peers).Debt / equity 0.91× vs peers 0.22× (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026

Mixed: some things better, some worse

Operating margin rose 20.3 points to 19.5%
Share count up 3.5% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4.4B USD	4.6B USD	+3.7%
Net income (12 months)	29.5M USD	940.8M USD	+3094.2%
Operating margin	-0.9%	19.5%	+20.3 pts
Free cash flow (12 months)	1.3B USD	1.6B USD	+25.3%
Debt	5.4B USD	4.4B USD	−18.7%
Cash	1.8B USD	1.6B USD	−12.2%
Shares outstanding	62.7M	64.9M	+3.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	5.5%	-1.8%	15.1%	17.6%	-10.1%	▼ 28 pts
Net margin	-10.7%	-6.1%	10.8%	13.8%	-8.3%	▼ 22 pts
Return on assets (ROA)	-2.7%	-2.1%	3.6%	4.7%	-3.1%	▼ 7.7 pts
Return on equity (ROE)	-8.3%	-7.3%	11.1%	13.7%	-8.2%	▼ 22 pts
Free cash flow margin	24.3%	34.0%	27.9%	33.4%	30.4%	▼ 3.0 pts
Current ratio	3.23×	2.79×	2.24×	4.46×	1.86×	▼ 58%
Quick ratio	1.90×	2.03×	1.85×	3.99×	1.67×	▼ 58%
Debt to equity	1.53×	1.86×	1.53×	1.49×	1.24×	▼ 17%
Interest coverage	1.89×	-2.00×	17.64×	—	—	—

JAZZ price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: higher risk than most peers: more debt relative to equity (0.91× vs a peer median of 0.22×)higher risk: more debt vs equity (0.91× vs peers 0.22×)

Ranks #238 of 1,157 healthcare companies (top 21%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $766M vs $706M spent repurchasing shares over the 3 fiscal years to 2025. Shares outstanding changed +2.7% from December 2022 to July 2026.

Over three fiscal years Jazz Pharmaceuticals recorded $766M of stock-based pay expense and spent $706M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Jazz Pharmaceuticals recorded $766M of stock-based pay expense and spent $706M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Jazz Pharmaceuticals made a profit per share in its latest year after a loss the year before.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $2.4B in 2020 to $4.3B in 2025.

Jazz Pharmaceuticals's fiscal-year revenue rose in each of the five years to 2025, from $2.4B to $4.3B.

Profit is backed by cash. Free cash flow is 169% of reported profit.

Jazz Pharmaceuticals's free cash flow is 169% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Jazz Pharmaceuticals

Is Jazz Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 3, 2026) was mixed: some things better, some worse: operating margin rose 20.3 points to 19.5%; share count up 3.5%. Its overall score is unchanged at 65/100 since Oct 28, 2026.

How is Jazz Pharmaceuticals valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 72/100 against 1,393 healthcare peers. Earnings yield 6.3% vs a peer median of 1.5% (stronger than 84% of peers).Earnings yield 6.3% vs peers 1.5% (stronger than 84% of peers).

Is Jazz Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 80/100 against 1,393 healthcare peers. Revenue growth 12.6% vs a peer median of 6.1% (stronger than 67% of peers).Revenue growth 12.6% vs peers 6.1% (stronger than 67% of peers).

How profitable is Jazz Pharmaceuticals?

More profitable than most of its peers. Profitability scores 79/100 against 1,393 healthcare peers. Return on assets 8.5% vs a peer median of 1.7% (stronger than 87% of peers).Return on assets 8.5% vs peers 1.7% (stronger than 87% of peers).

How risky is Jazz Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.36 vs a peer median of 0.63 (stronger than 73% of peers).Beta 0.36 vs peers 0.63 (stronger than 73% of peers). Debt / equity 0.91× vs a peer median of 0.22× (weaker than 79% of peers).Debt / equity 0.91× vs peers 0.22× (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4.4B USD

4.6B USD

+3.7%

Net income (12 months)

29.5M USD

940.8M USD

+3094.2%

Operating margin

-0.9%

19.5%

+20.3 pts

Free cash flow (12 months)

1.3B USD

1.6B USD

+25.3%

Debt

5.4B USD

4.4B USD

−18.7%

Cash

1.8B USD

1.6B USD

−12.2%

Shares outstanding

62.7M

64.9M

+3.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

5.5%

-1.8%

15.1%

17.6%

-10.1%

▼ 28 pts

Net margin

-10.7%

-6.1%

10.8%

13.8%

-8.3%

▼ 22 pts

Return on assets (ROA)

-2.7%

-2.1%

3.6%

4.7%

-3.1%

▼ 7.7 pts

Return on equity (ROE)

-8.3%

-7.3%

11.1%

13.7%

-8.2%

▼ 22 pts

Free cash flow margin

24.3%

34.0%

27.9%

33.4%

30.4%

▼ 3.0 pts

Current ratio

3.23×

2.79×

2.24×

4.46×

1.86×

▼ 58%

Quick ratio

1.90×

2.03×

1.85×

3.99×

1.67×

▼ 58%

Debt to equity

1.53×

1.86×

1.53×

1.49×

1.24×

▼ 17%

Interest coverage

1.89×

-2.00×

17.64×

—